Intra-Cellular Therapies (ITCI) PT Raised to $38 at BTIG
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Intra-Cellular Therapies (ITCI) PT Raised to $28 at SunTrust Robinson Humphrey; 'Adding Back Bipolar Depression'
March 2, 2018 9:03 AM ESTSunTrust Robinson Humphrey raised its price target on Intra-Cellular Therapies (NASDAQ: ITCI) to $28.00 (from $22.00) while maintaining a Buy rating.
Analyst Edward Nash commented, "Intra-Cellular will have a pre-NDA meeting with the FDA in 1Q18 for lumateperone for schizophrenia. Company expects to file NDA for... More
Intra-Cellular Therapies (ITCI) PT Raised to $28 at Cowen
March 2, 2018 1:23 AM ESTCowen raised its price target on Intra-Cellular Therapies (NASDAQ: ITCI) to $28.00 (from $27.00) while maintaining a Outperform rating.
... More